Methods for producing vaccine adjuvants

Abstract

An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

This application a type I (FIG. 5) followed by a type II (FIG. 6) circulation. For five separate runs the average number of larges larger particles per ml was as follows:

	Mean	Coefficient of variation
Type I	1.70 × 109	0.23
Type I followed by Type II	1.04 × 109	0.13

Thus the inclusion of type II circulation results in fewer large droplets and less batch-to-batch variation.

It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.

References

• [1] WO90/14837.
• [2] Podda & Del Giudice (2003) Expert Rev Vaccines 2:197-203.
• [3] Podda (2001) Vaccine 19: 2673-2680.
• [4] Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 (ISBN 0-306-44867-X).
• [5] Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series). ISBN: 1-59259-083-7. Ed. O'Hagan.
• [6] New Generation Vaccines (eds. Levine et al.). 3rd edition, 2004. ISBN 0-8247-4071-8.
• [7] O'Hagan (2007) Expert Rev Vaccines 6 (5):699-710.
• [8] EP-B-2029170
• [9] Baudner et al. (2009) Pharm Res. 26 (6):1477-85.
• [10] Dupuis et al. (1999) Vaccine 18:434-9.
• [11] Dupuis et al. (2001) Eur J Immunol 31:2910-8.
• [12] Burke et al. (1994) J Infect Dis 170:1110-9.
• [13] Light Scattering from Polymer Solutions and Nanoparticle Dispersions (W. Schartl), 2007. ISBN: 978-3-540-71950-2.
• [14] Jafari et al (2008) Food Hydrocolloids 22:1191-1202
• [15] WO90/04609.
• [16] U.S. Pat. No. 4,618,533
• [17] U.S. Pat. No. 6,193,077
• [18] U.S. Pat. No. 6,495,050
• [19] Chen et al. (1999) Journal of Applied Polymer Science, 72:1699-1711.
• [20] U.S. Pat. No. 4,413,074
• [21] U.S. Pat. No. 4,432,875
• [22] U.S. Pat. No. 4,340,482
• [23] U.S. Pat. No. 4,473,474
• [24] U.S. Pat. No. 4,473,475
• [25] U.S. Pat. No. 4,673,504
• [26] EP-A-0221046.
• [27] U.S. Pat. No. 4,943,374
• [28] U.S. Pat. No. 6,071,406
• [29] U.S. Pat. No. 4,705,753
• [30] U.S. Pat. No. 5,178,765
• [31] U.S. Pat. No. 6,495,043
• [32] U.S. Pat. No. 6,039,872
• [33] U.S. Pat. No. 5,277,812
• [34] U.S. Pat. No. 5,531,893.
• [35] U.S. Pat. No. 4,964,990
• [36] Wavhal & Fisher (2002) Journal of Polymer Science Part B: Polymer Physics 40:2473-88.
• [37] WO2006/044463.
• [38] Espinoza-Gómez et al. (2003) Revista de la Sociedad Quimica de México 47:53-57.
• [39] Lidgate et al (1992) Pharmaceutical Research 9 (7): 860-863.
• [40] US-2007/0014805.
• [41] WO2007/080308.
• [42] WO2007/052155.
• [43] WO2005/089837.
• [44] U.S. Pat. No. 6,692,468.
• [45] WO00/07647.
• [46] WO99/17820.
• [47] U.S. Pat. No. 5,971,953.
• [48] U.S. Pat. No. 4,060,082.
• [49] EP-A-0520618.
• [50] WO98/01174.
• [51] Hoffmann et al. (2002) Vaccine 20:3165-3170.
• [52] Subbarao et al. (2003) Virology 305:192-200.
• [53] Liu et al. (2003) Virology 314:580-590.
• [54] Ozaki et al. (2004) J. Virol. 78:1851-1857.
• [55] Webby et al. (2004) Lancet 363:1099-1103.
• [56] WO97/37000.
• [57] Brands et al. (1999) Dev Biol Stand 98:93-100.
• [58] Halperin et al. (2002) Vaccine 20:1240-7.
• [59] Tree et al. (2001) Vaccine 19:3444-50.
• [60] Kistner et al. (1998) Vaccine 16:960-8.
• [61] Kistner et al. (1999) Dev Biol Stand 98:101-110.
• [62] Bruhl et al. (2000) Vaccine 19:1149-58.
• [63] Pau et al. (2001) Vaccine 19:2716-21.
• [64] WO01/22992.
• [65] Hehme et al. (2004) Virus Res. 103 (1-2):163-71.
• [66] Treanor et al. (1996) J Infect Dis 173:1467-70.
• [67] Keitel et al. (1996) Clin Diagn Lab Immunol 3:507-10.
• [68] Williamson et al. (2006) Infection and Immunity 74:961-7.
• [69] Loukas et al. (2005) PLoS Med 2 (10): e295.
• [70] EP-A-0139417.
• [71] Harper et al. (2004) Lancet 364 (9447):1757-65.
• [72] J Toxicol Clin Toxicol (2001) 39:85-100.
• [73] Demicheli et al. (1998) Vaccine 16:880-884.
• [74] Stepanov et al. (1996) J Biotechnol 44:155-160.
• [75] Banzhoff (2000) Immunology Letters 71:91-96.
• [76] WO02/097072.
• [77] Greenbaum et al. (2004) Vaccine 22:2566-77.
• [78] Zurbriggen et al. (2003) Expert Rev Vaccines 2:295-304.
• [79] Piascik (2003) J Am Pharm Assoc (Wash DC). 43:728-30.
• [80] Mann et al. (2004) Vaccine 22:2425-9.
• [81] Halperin et al. (1979) Am J Public Health 69:1247-50.
• [82] Herbert et al. (1979) J Infect Dis 140:234-8.
• [83] Chen et al. (2003) Vaccine 21:2830-6.

Claims

1. A method for the manufacture of a squalene-containing oil-in-water emulsion vaccine adjuvant, the method comprising the step of: (i) formation of a first emulsion having a first average oil droplet size using a mechanical homogenizer, wherein the first emulsion is formed by a type ii circulation of transferring its the first emulsion components from a first container to a second container through a homogenizer, and then returning them from the second container to the first container through the same homogenizer, wherein substantially all of the emulsion components from the first container are passed through the homogenizer into the second container, and then substantially all of the emulsion components from the second container are passed through the homogenizer back into the first container; and (ii) microfluidizing the first emulsion to form a second emulsion having a second average oil droplet size which is less than the first average oil droplet size.

2. The method of claim 1, wherein step (i) comprises two or more cycles of transferring the first emulsion's components from the first container to the second container and back again.

3. The method of claim 1, wherein the homogenizer is a rotor-stator homogenizer and wherein the microfluidization occurs in an interaction chamber having no moving parts.

4. The method of claim 1, wherein the homogenizer provides a shear rate of up to 1×10⁶ s⁻¹, and wherein the microfluidization occurs an interaction chamber that provides a shear rate >2.5×10⁶ s⁻¹.

5. The method of claim 1, comprising: (iii) filtration of the second emulsion.

6. The method of claim 1, wherein during step (ii), the second emulsion is formed by circulating the second emulsion components through a microfluidization device a plurality of times.

7. The method of claim 6, wherein the circulation of the second emulsion components comprises transferring the second emulsion components between a first emulsion container and a microfluidization device; and (iii) microfluidizing the first emulsion to form a second emulsion having a second average oil droplet size which is less than the first average oil droplet size.

8. The method of claim 6, wherein the circulation of the second emulsion components comprises transferring the second emulsion components from a first emulsion container, through a microfluidization device to a second emulsion container, and then again through the microfluidization device.

9. The method of claim 1, wherein the first average oil droplet size is 5000 nm or less.

10. The method according to claim 1, wherein the number of oil droplets having a size of >1.2 μm in the first emulsion is 5×10¹¹/ml or less.

11. The method of claim 1, wherein the second average oil droplet size is 500 nm or less.

12. The method of claim 1, further comprising combining the emulsion with an antigen to produce a vaccine composition.

13. The method of claim 1, further comprising packaging the emulsion into a kit as a kit component together with an antigen component.

14. The method of claim 1, wherein the components of the first emulsion are combined in a mixing vessel before being introduced into the homogenizer.

15. The method of claim 14, wherein the homogenizer is a rotor-stator homogenizer.

16. The method of claim 1, wherein the first and second containers are held under an inert gas.

17. The method of claim 6, wherein the second emulsion is formed by circulating the second emulsion components through a microfluidization device three times.

18. The method of claim 1, wherein the first and second emulsion containers are held under an inert gas.

19. The method of claim 1, wherein the first emulsion is formed by circulation comprising (a) a type I circulation of transferring the first emulsion components between a first container and a homogenizer followed by (b) the type ii circulation.